Commonwealth Serum Laboratories Regulations (Amendment)

Overview

The Commonwealth Serum Laboratories Regulations 1965, enacted under the Commonwealth Serum Laboratories Act 1961, were introduced to amend the existing regulations governing the manufacture and supply of certain biological products. These amendments were made in response to the need to update the list of regulated substances to include new pharmaceuticals such as neomycin and polymyxin, as well as to introduce controls over digitalis and rauwolfia products, which are derived from specific plants and used in various medical treatments. The regulations were established by the Governor-General in Council, acting on the advice of the relevant ministers, to ensure the safety and efficacy of these products within the Australian healthcare system. The policy objective was to provide a comprehensive regulatory framework that maintains high standards for the production and distribution of essential biological products in Australia.

Scope and Application

The Commonwealth Serum Laboratories Act 1961, as amended by the Statutory Rules 1965, No. 148, applies to the Commonwealth Serum Laboratories (CSL) and its activities, which include the production, quality control, and distribution of biological products. These regulations pertain specifically to the regulation of substances and products under CSL's purview, affecting entities involved in the manufacture or distribution of biological products within the Commonwealth of Australia. The scope of this legislation extends to the inclusion of additional substances, such as Neomycin and Polymyxin, into the regulated items list, as well as the addition of Digitalis and Rauwolfia products and their preparations. These regulations are designed to ensure the safety and efficacy of biological products, thereby impacting industries involved in the production and distribution of these substances. The geographic reach of these regulations is national, applying uniformly across Australia. There are no stated exclusions or exemptions in the provided text, and the application of the Act is extended through the amendments made in the Statutory Rules 1965, No. 148.

Key Provisions

The main operative sections of this Statutory Rule (No. 148) involve amendments to the Commonwealth Serum Laboratories Regulations under the Commonwealth Serum Laboratories Act 1961. Specifically, these amendments pertain to the inclusion of new substances within the regulation of controlled items. Under Item 6, sub-items (8) and (9) have been added to include "Neomycin" and "Polymyxin" respectively (Item 6(8), Item 6(9)). Similarly, Item 7 has been amended to include sub-items (9) and (10) for "Neomycin" and "Polymyxin" (Item 7(9), Item 7(10)). Additionally, new items 16a and 16b have been inserted, listing "Digitalis and other biological products derived from the plant Digitalis purpurea or the plant Digitalis lanata, and preparations containing Digitalis or such a product" and "Rauwolfia and other biological products derived from the plant Rauwolfia serpentina or the plant Rauwolfia vomi-toria, and preparations containing Rauwolfia or such a product" respectively (Item 16a, Item 16b). The obligations and requirements imposed by these amendments necessitate that any person or entity involved in the manufacture, distribution, or sale of these newly regulated substances must comply with the provisions set out in the Commonwealth Serum Laboratories Regulations. This includes adhering to any specified standards, quality controls, and regulatory oversight mechanisms established under the Act. Additionally, these entities must ensure that all operations involving these substances are conducted in a manner that aligns with the regulatory framework, including proper documentation, reporting, and compliance with any licensing or permit requirements. The Statutory Rule also outlines consequences for non-compliance with the amended regulations. Any breach of these provisions could lead to civil or criminal penalties. While the exact penalties are not specified within the text of the Statutory Rule, under the Commonwealth Serum Laboratories Act 1961, penalties for non-compliance can include fines and, in severe cases, imprisonment. The precise penalties would depend on the nature and severity of the breach, as well as any additional provisions within the Act or other relevant legislation that might apply.